Immunomedics Announces FDA Orphan Drug Designation of Trodelvy™ for Adult and Pediatric Glioblastoma
12 oct. 2020 08h00 HE
|
Immunomedics
MORRIS PLAINS, N.J., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study of Trodelvy™ in Metastatic Urothelial Cancer
19 sept. 2020 11h00 HE
|
Immunomedics
Trodelvy achieves a 27 percent overall response rate and a 5.9-month median duration of response in heavily-pretreated patients with metastatic urothelial cancer (mUC) sBLA submission for accelerated...
Trodelvy™ Significantly Extends Survival in Phase 3 ASCENT Study of Metastatic Triple-Negative Breast Cancer
19 sept. 2020 10h30 HE
|
Immunomedics
Trodelvy significantly reduced the risk of death by 52 percent, with a median overall survival (OS) of 12.1 months compared to 6.7 months for standard single-agent chemotherapy Trodelvy is the...
Immunomedics Announces Encouraging Early-Stage Clinical Results with Trodelvy™ in Brain Cancers
18 sept. 2020 08h00 HE
|
Immunomedics
MORRIS PLAINS, N.J., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics Announces Key Oral Presentations at ESMO Virtual Congress 2020
09 sept. 2020 07h00 HE
|
Immunomedics
Breadth of presentations include i) Full results from ASCENT; ii) Final results from TROPHY U-01 cohort 1; iii) First results with Trodelvy™ in brain tumors Conference call and webcast with key...
Immunomedics to Participate in Upcoming Healthcare Conferences
02 sept. 2020 08h00 HE
|
Immunomedics
MORRIS PLAINS, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics Announces FDA Approval of Samsung Biologics as Antibody Manufacturer for Trodelvy™
17 août 2020 08h00 HE
|
Immunomedics
MORRIS PLAINS, N.J., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics Reports Second Quarter 2020 Results and Provides Corporate Update
05 août 2020 16h00 HE
|
Immunomedics
Encouraging early adoption of Trodelvy™ in U.S. with $20.1M net sales in first two months of launch Confirmatory Phase 3 ASCENT study met primary endpoint of progression-free survival and key...
Immunomedics to Report Second Quarter 2020 Results and Host Conference Call and Webcast on August 5, 2020
27 juil. 2020 08h00 HE
|
Immunomedics
MORRIS PLAINS, N.J., July 27, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics Expands Collaboration with Roche Evaluating Trodelvy™ (sacituzumab govitecan-hziy) in Combination with Tecentriq® (atezolizumab) into Urothelial and Non-Small Cell Lung Cancers
13 juil. 2020 16h00 HE
|
Immunomedics
Companies have ongoing collaboration in first-line metastatic triple-negative breast cancer Immunomedics also announces Phase 2 NeoSTAR study in neoadjuvant triple-negative breast cancer has begun...